Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Los Angeles Times - February 3, 2009
Melissa Healy
A new study by pharmacologists and physicians at the University of Southern California found that, in animals as well as in the test tube, certain constituents of green tea blocked the effects of bortezomib -- notably, the drug's ability to induce tumor cells to die off. Bortezomib, or Velcade, is a boronic acid proteasome inhibitor. It was first approved by the FDA in 2003 as a last-ditch drug for myeloma patients, but is now recognized as a first-line drug against mantle cell lymphoma and multiple myeloma.
The USC study found that green tea appears to interfere only with boronic-acid proteasome inhibitors such as Velcade, but not with non-boronic proteasome inhibitors, including the drug nelfinavir, a medicine for use in HIV/AIDS patients.
The finding that green tea's constituents had a "pronounced antagonistic function" when combined with the cancer drug was a major surprise. Researchers -- responding to optimism in the cancer research and patient communities over the curative potential of green tea -- set out to investigate whether the combination of green tea and bortezomib would yield "increased antitumor efficacy" over bortezomib alone. Instead they found that green tea's polyphenols "have the potential to negate the therapeutic efficacy" of bortezomib against cancerous cell lines that give rise to glioblastoma and multiple myeloma.
090203
LT090201
Copyright © 2009 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .